Li Hao, Dai Wenni, Liu Zhiwen, He Liyu
Department of Nephrology, The Second Xiangya Hospital of Central South University, Hunan Key Laboratory of Kidney Disease and Blood Purification, Changsha 410011, Hunan, China.
Pharmaceuticals (Basel). 2022 Nov 30;15(12):1494. doi: 10.3390/ph15121494.
Diabetic kidney disease (DKD) is a major complication of diabetes mellitus (DM) and the leading cause of end-stage kidney disease (ESKD) worldwide. A significant number of drugs have been clinically investigated for the treatment of DKD. However, a large proportion of patients still develop end-stage kidney disease unstoppably. As a result, new effective therapies are urgently needed to slow down the progression of DKD. Recently, there is increasing evidence that targeted drug delivery strategies such as large molecule carriers, small molecule prodrugs, and nanoparticles can improve drug efficacy and reduce adverse side effects. There is no doubt that targeted drug delivery strategies have epoch-making significance and great application prospects for the treatment of DKD. In addition, the proximal tubule plays a very critical role in the progression of DKD. Consequently, the purpose of this paper is to summarize the current understanding of proximal tubule cell-targeted therapy, screen for optimal targeting strategies, and find new therapeutic approaches for the treatment of DKD.
糖尿病肾病（DKD）是糖尿病（DM）的主要并发症，也是全球终末期肾病（ESKD）的主要病因。大量药物已在临床上进行了治疗DKD的研究。然而，仍有很大一部分患者不可阻挡地发展为终末期肾病。因此，迫切需要新的有效疗法来减缓DKD的进展。最近，越来越多的证据表明，大分子载体、小分子前药和纳米颗粒等靶向给药策略可以提高药物疗效并减少不良反应。毫无疑问，靶向给药策略对DKD的治疗具有划时代的意义和巨大的应用前景。此外，近端小管在DKD的进展中起着非常关键的作用。因此，本文的目的是总结目前对近端小管细胞靶向治疗的认识，筛选最佳靶向策略，并寻找治疗DKD的新方法。
